X4 Pharmaceuticals, Inc (XFOR)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 1,973 | 28,807 | 560 | 563 |
| Gain on sale of non-financial asset (note 17) | - | - | - | 105,000 |
| Research and development | 18,352 | 18,513 | 19,173 | 20,914 |
| Selling, general and administrative | 9,527 | 15,021 | 15,660 | 13,278 |
| Gain on sale of non-financial asset (note 17) | - | - | - | - |
| Cost of revenue | 326 | 4,716 | 227 | 268 |
| Total operating expense (income) | -28,205 | -38,250 | -35,060 | 70,540 |
| Loss from operations | -26,232 | -9,443 | -34,500 | 71,103 |
| Interest expense | - | - | 2,414 | 2,176 |
| Other (expense) income, net | -547 | 105 | 226 | 144 |
| Interest income | 665 | 1,025 | 1,871 | 1,565 |
| Interest expense | 2,232 | 2,201 | - | - |
| Change in fair value of warrant liability | 2,642 | 10,830 | -1,864 | 20,215 |
| Total other income, net | 528 | 9,759 | -2,181 | 19,748 |
| (loss) income before provision for income taxes | -25,704 | 316 | -36,681 | 90,851 |
| Provision for income taxes | 37 | 34 | 15 | 18 |
| Net (loss) income | -25,741 | 282 | -36,696 | 90,833 |
| Net loss per share attributable to common stockholdersbasic | -3.47 | 0.04 | -0.18 | 0.45 |
| Net loss per share attributable to common stockholdersdiluted | -3.47 | 0.04 | -0.18 | 0.45 |
| Weighted average shares of common stock outstandingbasic | 7,412,990 | 6,840,035 | 200,865,276 | 200,440,473 |
| Weighted average shares of common stock outstandingdiluted | 7,412,990 | 6,869,084 | 200,865,276 | 200,801,311 |